Bayer Acquires HiDoc Technologies and Cara Care® App for Irritable Bowel Syndrome

BayerBayer is today announcing that it plans to acquire HiDoc Technologies GmbH in the first quarter of 2025 and to start commercialization of the digital health application, Cara Care®. Cara Care® is the first prescribed digital health application for the treatment of irritable bowel syndrome (IBS) and offers a novel, holistic therapeutic approach for patients with IBS.(1)

Patients with irritable bowel syndrome have generally already been through a lot by the time they receive a formal diagnosis, and they face numerous daily challenges and obstacles associated with their symptoms that impair their quality of life. To be able to provide patients with a personalized, independent concept of supplementary guideline-compliant therapeutic offerings in addition to medical treatment and pharmacological therapy, Bayer has acquired HiDoc Technologies GmbH and taken over the commercialization of its digital health application Cara Care®. Thanks to its personalized modules, patients learn to understand their condition better, as well as getting better control over the symptoms and achieving an improved quality of life.

Cara Care®: guideline-compliant personalized therapy

Irritable bowel syndrome affects approximately 11.1 percent of the population in Germany and represents a considerable burden for these patients.(5) Treatment is often difficult, as the underlying pathophysiology is complex, and symptom patterns and severities vary from patient to patient.(4) In addition to pharmacological therapy, such as treatment with plant-based pharmaceuticals such as Iberogast®, the current German S3 guideline recommends a multimodal and multidisciplinary therapeutic model comprising additional components, such as psychology and dietary recommendations.(4)

Cara Care® is the first prescribed digital health application for irritable bowel syndrome and offers patients with IBS a novel, holistic approach.(1) The app integrates multidisciplinary approaches for the treatment of gastrointestinal symptoms such as stomach and irregular bowel movements. Based on the recommendations of the S3 guideline, apps like Cara Care® provide an educational model with information on the disease and evidence-based support in the non-pharmaceutical therapeutic areas of diet and psychotherapeutic options, along with support for sufferers in the form of personalized therapy plans.(1-4)

Support for patients with irritable bowel syndrome

The digital health application Cara Care® represents a valuable addition to healthcare professionals' (HCPs) repertoire for treating irritable bowel syndrome. Cara Care® features integrated "Diet" and "Psychology" elements in a biopsychosocial model to enable comprehensive care of IBS sufferers. Patients can undergo the treatment autonomously and receive targeted support, thus increasing their competency in living with their condition. The prescription app is budget-neutral and does not require additional payment for patients.

"The Cara Care digital health app is another important therapeutic component that enables physicians to provide sustainable, guideline-compliant care for their patients," explains Linda Obermeyr, Senior HCP Marketing Manager at Bayer Vital. "We are confident that with the digital support of the Cara Care app, patients will be able to expand their own understanding and modify their behavior to find effective relief from the symptoms of IBS and return to a markedly higher quality of life."

For patients, Cara Care® offers an individualized, tailor-made, evidence-based therapy based on medical questionnaires and enabling a personalized modular setup. Additional features like tracking and personalized recipe ideas help patients with their therapy. What’s more, the digital health application also addresses psychological co-morbidities such as anxiety and depression, which often cannot be taken into consideration in everyday clinical practice. Treatment with Cara Care® is time- and location-neutral, and represents a valuable addition, or follow-up, to existing therapies. It also helps patients cope with disease-related challenges in daily life.

"We saw an opportunity to combine a strong, scientifically sound app with our many years of experience in the field of gastroenterology, and in this way to create added value for patients. We will work to make sure that this digital health application becomes even more user-friendly and instructive through training sessions, test accounts, videos and dialogs with Bayer's field force," explains Tobias Boldt, Cluster Head Germany & Austria Consumer Health, Bayer Vital.

Bayer extends portfolio with new digital therapeutic option

"IBS is common and highly disruptive to sufferers, but its complexity means that many patients struggle to understand the condition, risk factors and preventive measures," explains David Evendon-Challis, Head of R&D and Strategic Marketing & Digital for Bayer's Consumer Health Division. "This latest milestone in our precision health strategy means that we will be able to offer a digital tool to help them understand, manage and treat their IBS better. It will also give them greater control over the condition by facilitating conversations with their HCP."

The planned strategic acquisition of HiDoc Technologies expands Bayer’s portfolio in the field of digital healthcare and extends the company’s engagement in the area of self-medication. "Many people are looking for ways to become more self-reliant, and that applies to the area of healthcare as well. Digital health applications are a good way of providing holistic, sustainable therapeutic approaches. This was always our goal for Cara Care and it is also perfectly in line with Bayer's vision of 'Health for all, Hunger for none'," said Jim Mapes, the CEO of HiDoc Technologies.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros.

About HiDoc Technologies GmbH and Cara Care

HiDoc Technologies GmbH is an innovative digital health company based in Hamburg, Germany, specializing in the development and provision of digital health solutions. As a pioneer in the field of digital health applications, HiDoc developed Cara Care for irritable bowel syndrome, the first and currently only approved digital health application for this condition in Germany.

The company combines current technology with scientifically-based therapy to offer patients with chronic complaints such as irritable bowel syndrome a customized and flexible treatment option. HiDoc Technologies GmbH's vision is to provide people worldwide with access to holistic digital therapy approaches, thereby sustainably improving healthcare.

* Digital health applications are innovative, medical apps that help patients recognize, monitor and treat diseases.1-3 They are reviewed by the German Federal Institute for Drugs and Medical Devices (BfArM) and registered as medical devices (permanently listed in accordance with the Digital Health Application Ordinance) to ensure that they are safe and effective.

1. Weißer LM, et al. Poster presentation at DDW 2022, San Diego, USA.
2. Tayana J, et al. Scientific Reports 2024;14(4).
3. Brenner DM, et al. Clinical Gastroenterology and Hepatology 2022;22(2):222-234.
4. Layer P et al. Z Gastroenterol 2021;59:1323-1415.
5. Sperber et. al. Gastroenterology 2021;160:99-114.
6. BARMER Arztreport 2024, retrieved on 16.07.2024 [online at: https://www.bifg.de/publikationen/reporte/arztreport-2024]

Most Popular Now

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...